The DOI matches its Crossref record; 260 of the 260 references it cites were found in a registry or an index.
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Open accessAbstract
Tumor cells develop resistance to chemotherapeutic drugs through multiple mechanisms. Overexpression of efflux transporters is an important source of drug resistance. Efflux transporters such as P-glycoprotein reduce intracellular drug accumulation and compromise drug efficacy. Various nanoparticle-based approaches have been investigated to overcome efflux-mediated resistance. These include the use of formulation excipients that inhibit transporter activity and co-delivery of the anticancer drug with a specific inhibitor of transporter function or expression. However, the effectiveness of nanoparticles can be diminished by poor transport in the tumor tissue. Hence, adjunct therapies that improve the intratumoral distribution of nanoparticles may be vital to the successful application of nanotechnology to overcome tumor drug resistance. This review discusses the mechanisms of tumor drug resistance and highlights the opportunities and challenges in the use of nanoparticles to improve the efficacy of anticancer drugs against resistant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 3×
“While tumor cells evade death through multiple mechanisms [3], overexpression of efflux transporters is an important source of drug resistance.”
BackgroundBlock copolymer micelles for drug delivery: design, characterization and biological significance
Kataoka, K., Harada, A., & Nagasaki, Y. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00124-1 · Cited by 3,506
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Cited by
Della Torre, C., Bergami, E., Salvati, A., Faleri, C., Cirino, P., Dawson, K. A., & Corsi, I. (2014) · Environmental Science & Technology · doi:10.1021/es502569w · Cited by 632
Recent advances in functional nanomaterials for light–triggered cancer therapy
Gai, S., Yang, G., Yang, P., He, F., Lin, J., Jin, D., & Xing, B. (2018) · Nano Today · doi:10.1016/j.nantod.2018.02.010 · Cited by 568
Miao, T., Wang, J., Zeng, Y., Liu, G., & Chen, X. (2018) · Advanced Science · doi:10.1002/advs.201700513 · Cited by 362
Chen, L., Zhou, L., Wang, C., Han, Y., Lu, Y., Liu, J., Hu, X., Yao, T., Lin, Y., Liang, S., et al. (2019) · Advanced Materials · doi:10.1002/adma.201904997 · Cited by 337
An O2 Self‐Sufficient Biomimetic Nanoplatform for Highly Specific and Efficient Photodynamic Therapy
Cheng, H., Zhu, J., Li, S., Zeng, J., Lei, Q., Chen, K., Zhang, C., & Zhang, X. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201603212 · Cited by 335
Synthesis of Silver Nanoparticles and their Biomedical Applications - A Comprehensive Review
Shanmuganathan, R., Karuppusamy, I., Saravanan, M., Muthukumar, H., Ponnuchamy, K., Ramkumar, V. S., & Pugazhendhi, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190708185506 · Cited by 282
He, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
Influencing factors and strategies of enhancing nanoparticles into tumors in vivo
Zhang, M., Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Liu, Y., Liu, X., Su, K., & Shi, K. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.033 · Cited by 274
Zhong, X., Yang, K., Dong, Z., Yi, X., Wang, Y., Ge, C., Zhao, Y., & Liu, Z. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201503587 · Cited by 265
Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors
Miao, L., Lin, C. M., & Huang, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.017 · Cited by 264
Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review
Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.041 · Cited by 263
Du, X., Li, X., Xiong, L., Zhang, X., Kleitz, F., & Qiao, S. Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.019 · Cited by 262
Current trends in using polymer coated gold nanoparticles for cancer therapy
Muddineti, O. S., Ghosh, B., & Biswas, S. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.038 · Cited by 259
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
Recent advances in drug delivery systems for targeting cancer stem cells
Duan, H., Liu, Y., Gao, Z., & Huang, W. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.016 · Cited by 256
Yu, H., Cui, Z., Yu, P., Guo, C., Feng, B., Jiang, T., Wang, S., Yin, Q., Zhong, D., Yang, X., et al. (2015) · Advanced Functional Materials · doi:10.1002/adfm.201404484 · Cited by 253
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Combination therapy based on nano codelivery for overcoming cancer drug resistance
Wang, H., & Huang, Y. (2020) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2020.100024 · Cited by 115
Kirtane, A. R., Sadhukha, T., Kim, H., Khanna, V., Koniar, B., & Panyam, J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1646 · Cited by 38
Self-citationAssessing the benefits of drug delivery by nanocarriers: a partico/pharmacokinetic framework
Siegel, R. A., Kirtane, A. R., & Panyam, J. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2632733 · Cited by 14
Self-citation
Metadata
- Authors
- Kirtane, A. R., Kalscheuer, S. M., & Panyam, J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-11
- Volume
- 65
- Issue
- 13-14
- Pages
- 1731-1747
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2050564805
- Cited by
- 258
- References
- 260
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.